Alan Cooper
he/him/his
About
Research
Publications
2025
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, Venkataraman G, Zha Y, Pelzer B, Song J, Duns G, Sworder B, Raj S, Bolen C, Penuel E, Postovalova E, Kotlov N, Bagaev A, Fowler N, Shouval R, Smith S, Alizadeh A, Steidl C, Kline J. Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood 2025, 145: 2460-2472. PMID: 39869833, PMCID: PMC12163739, DOI: 10.1182/blood.2024025355.Peer-Reviewed Original Research
2024
Inhibition of PI3Kγ/δ signaling promotes an early memory state in CAR T cells and enhances their in vivo persistence and efficacy
Rojek A, Xie L, Cooper A, Chen X, Riedell P, Bishop M, Kline J. Inhibition of PI3Kγ/δ signaling promotes an early memory state in CAR T cells and enhances their in vivo persistence and efficacy. International Journal Of Cancer Care And Delivery 2024 DOI: 10.53876/001c.123862.Peer-Reviewed Original ResearchT-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses.
Chen X, Yu J, Venkataraman G, Smith S, Chen M, Cooper A, Tumuluru S, Brody J, Godfrey J, Kline J. T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses. Cancer Immunology Research 2024, 12: 296-307. PMID: 38240659, DOI: 10.1158/2326-6066.cir-23-0547.Peer-Reviewed Original Research
2023
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition
Cooper A, Tumuluru S, Kissick K, Venkataraman G, Song J, Lytle A, Duns G, Yu J, Kotlov N, Bagaev A, Hodkinson B, Srinivasan S, Smith S, Scott D, Steidl C, Godfrey J, Kline J. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition. Journal Of Clinical Oncology 2023, 42: 467-480. PMID: 38079587, DOI: 10.1200/jco.23.01574.Peer-Reviewed Original ResearchTIGIT is a key inhibitory checkpoint receptor in lymphoma
Godfrey J, Chen X, Sunseri N, Cooper A, Yu J, Varlamova A, Zarubin D, Popov Y, Jacobson C, Postovalova E, Xiang Z, Nomie K, Bagaev A, Venkataraman G, Zha Y, Tumuluru S, Smith S, Kline J. TIGIT is a key inhibitory checkpoint receptor in lymphoma. Journal For ImmunoTherapy Of Cancer 2023, 11: e006582. PMID: 37364933, PMCID: PMC10410806, DOI: 10.1136/jitc-2022-006582.Peer-Reviewed Original ResearchPembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation
Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz A, Riedell P, Stock W, Karrison T, Fitzpatrick C, Venkataraman G, Cooper A, Smith S, Bishop M, Kline J. Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation. Blood Advances 2023, 7: 963-970. PMID: 35973200, PMCID: PMC10027501, DOI: 10.1182/bloodadvances.2022008403.Peer-Reviewed Original ResearchThe lymphoma microenvironment comes of age in the R-CHOP era?
Cooper A, Kline J. The lymphoma microenvironment comes of age in the R-CHOP era? Haematologica 2023, 108: 1986-1987. PMID: 36924323, PMCID: PMC10388257, DOI: 10.3324/haematol.2022.282656.Commentaries, Editorials and Letters
Links
Get In Touch
Contacts
Email